New LaunchAug 6, 2026, 08:35 AM
RenovoRx RenovoCath Used for Sarcoma Treatment at CARTI
AI Summary
RenovoRx announced the first commercial clinical use of its FDA-cleared RenovoCath device for drug delivery in the treatment of a sarcoma patient at CARTI Cancer Center. This marks an important milestone, demonstrating the device's potential for other solid tumors beyond its core focus on pancreatic cancer. The company also reported approximately $1.1 million in RenovoCath sales for 2025 and $563,000 in Q1 2026, while anticipating full enrollment in its Phase III TIGeR-PaC trial soon.
Key Highlights
- First commercial clinical use of RenovoCath for sarcoma treatment at CARTI Cancer Center.
- RenovoCath is also being used for localized drug delivery in pancreatic cancer treatment at CARTI.
- RenovoRx generated approximately $1.1 million in RenovoCath sales in 2025.
- RenovoRx reported $563,000 in RenovoCath sales for the first quarter of 2026.
- Anticipates full enrollment in the Phase III TIGeR-PaC trial in the very near term.
- Final data readout for the TIGeR-PaC trial expected in mid to late 2027.
Price Impact
More from RNXT